āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2
BURLINGAME, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today a...
How does this partnership position MREO relative to competitors developing therapies for rare bone and connective tissue disorders?
What is the expected timeline for clinical development and potential FDA approval of vantictumab for autosomal dominant osteopetrosis type 2?
How will the exclusive licensing of vantictumab affect Mereo BioPharma's (MREO) revenue outlook and earnings guidance?
8 days ago